Advertisement

Analytical and Bioanalytical Chemistry

, Volume 405, Issue 19, pp 6307–6321 | Cite as

Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MS n

  • Markus R. Meyer
  • Martina Bach
  • Jessica Welter
  • Michael Bovens
  • Alain Turcant
  • Hans H. Maurer
Research Paper

Abstract

Methoxetamine (MXE; 2-(3-methoxyphenyl)-2-(N-ethylamino)-cyclohexanone), a ketamine analog, is a new designer drug and synthesized for its longer lasting and favorable pharmacological effects over ketamine. The aims of the presented study were to identify the phases I and II metabolites of MXE in rat and human urine by GC-MS and LC-high-resolution (HR)-MS n and to evaluate their detectability by GC-MS and LC-MS n using authors’ standard urine screening approaches (SUSAs). Furthermore, human cytochrome P450 (CYP) enzymes were identified to be involved in the initial metabolic steps of MXE in vitro, and respective enzyme kinetic studies using the metabolite formation and substrate depletion approach were conducted. Finally, human urine samples from forensic cases, where the ingestion of MXE was suspected, were analyzed. Eight metabolites were identified in rat and different human urines allowing postulation of the following metabolic pathways: N-deethylation, O-demethylation, hydroxylation, and combinations as well as glucuronidation or sulfation. The enzyme kinetic studies showed that the initial metabolic step in humans, the N-deethylation, was catalyzed by CYP2B6 and CYP3A4. Both SUSAs using GC-MS or LC-MS n allowed monitoring an MXE intake in urine.

Keywords

Designer drugs Methoxetamine MXE Cytochrome P450 GC-MS LC-MS 

Notes

Acknowledgments

The authors like to thank Gabriele Ulrich, Carsten Schröder, and Armin A. Weber for their support.

Supplementary material

216_2013_7051_MOESM1_ESM.pdf (833 kb)
ESM 1 (PDF 833 kb)

References

  1. 1.
    Hofer KE, Grager B, Muller DM, Rauber-Luthy C, Kupferschmidt H, Rentsch KM, Ceschi A (2012) Ann Emerg Med 60:97–99CrossRefGoogle Scholar
  2. 2.
    Archer JR, Dargan PI, Hudson S, Wood DM (2013) QJM 106:147–152CrossRefGoogle Scholar
  3. 3.
    Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, Corkery J, Trincas G, Deluca P, Davey Z, Blaszko U, Demetrovics Z, Moskalewicz J, Enea A, di Melchiorre G, Mervo B, di Furia L, Farre M, Flesland L, Pasinetti M, Pezzolesi C, Pisarska A, Shapiro H, Siemann H, Skutle A, Enea A, di Melchiorre G, Sferrazza E, Torrens M, van der Kreeft P, Zummo D, Scherbaum N (2012) Hum Psychopharmacol 27:145–149CrossRefGoogle Scholar
  4. 4.
    Coppola M, Mondola R (2012) Med. Hypotheses 79:504–507CrossRefGoogle Scholar
  5. 5.
    Hill SL, Harbon SC, Coulson J, Cooper GA, Jackson G, Lupton DJ, Vale JA, and Thomas SH (2013) Emerg Med J (in press)Google Scholar
  6. 6.
    Rosenbaum CD, Carreiro SP, Babu KM (2012) J Med Toxicol 8:15–32CrossRefGoogle Scholar
  7. 7.
    The Guardian (2012) The Guardian. http://www.guardian.co.uk/society/2012/mar/28/legal-high-drug-methoxetamine-banned. Accessed 26 Feb 2013
  8. 8.
    Bundesinstitut für Arzneimittel und Medizinprodukte (2012). http://www.bfarm.de/DE/Bundesopiumstelle/BtM/sachverst/Protokolle/Ergebnisse_39.html. Accessed Feb 2013 2606
  9. 9.
    Wikstrom M, Thelander G, Dahlgren M, Kronstrand R (2013) J Anal Toxicol 37:43–46CrossRefGoogle Scholar
  10. 10.
    Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan PI (2012) Eur J Clin Pharmacol 68:853–856CrossRefGoogle Scholar
  11. 11.
    Misselbrook GP, Hamilton EJ (2012) Acute Med 11:157–160Google Scholar
  12. 12.
    Sein AJ, Wiergowski M, Barwina M, Kaletha K (2012) Przegl Lek 69:609–610Google Scholar
  13. 13.
    Shields JE, Dargan PI, Wood DM, Puchnarewicz M, Davies S, Waring WS (2012) Clin Toxicol (Phila) 50:438–440CrossRefGoogle Scholar
  14. 14.
    Westwell AD, Hutchings A, and Caldicott DG (2013) Drug Test Anal (in press)Google Scholar
  15. 15.
    Welter J, Meyer MR, Wolf E, Weinmann W, Kavanagh P, and Maurer HH (2013) Anal Bioanal Chem. doi  10.1007/s00216-013-6741-4
  16. 16.
    Maurer HH, Pfleger K, Weber AA (2011) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley, WeinheimGoogle Scholar
  17. 17.
    Ewald AH, Ehlers D, Maurer HH (2008) Anal Bioanal Chem 390:1837–1842CrossRefGoogle Scholar
  18. 18.
    Maurer HH, Pfleger K, Weber AA (2011) Mass spectral library of drugs, poisons, pesticides, pollutants and their metabolites. Wiley, WeinheimGoogle Scholar
  19. 19.
    Meyer MR, Peters FT, Maurer HH (2010) Clin Chem 56:575–584CrossRefGoogle Scholar
  20. 20.
    Wissenbach DK, Meyer MR, Remane D, Weber AA, Maurer HH (2011) Anal Bioanal Chem 400:79–88CrossRefGoogle Scholar
  21. 21.
    Meyer MR, Vollmar C, Schwaninger AE, Maurer HH (2012) J Mass Spectrom 47:253–262CrossRefGoogle Scholar
  22. 22.
    Schwaninger AE, Meyer MR, Maurer HH (2011) Drug Metab. Dispos 39:1998–2002CrossRefGoogle Scholar
  23. 23.
    Obach RS, Reed-Hagen AE (2002) Drug Metab Dispos 30:831–837CrossRefGoogle Scholar
  24. 24.
    Crespi CL, Miller VP (1999) Pharmacol Ther 84:121–131CrossRefGoogle Scholar
  25. 25.
    Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, Greenblatt DJ (2000) Drug Metab. Dispos 28:1493–1504Google Scholar
  26. 26.
    Grime K, Riley RJ (2006) Curr. Drug Metab 7:251–264CrossRefGoogle Scholar
  27. 27.
    Hays PA, Casale JF, Berrier AL (2012) Microgram J 9:3–17Google Scholar
  28. 28.
    McLafferty FW, Turecek F (1993) Interpretation of mass spectra. University Science Books, Mill Valley, CAGoogle Scholar
  29. 29.
    Smith RM, Busch KL (1999) Understanding mass spectra—a basic approach. Wiley, New York (NY)Google Scholar
  30. 30.
    de Zeeuw RA, Franke JP, Maurer HH, Pfleger K (1992) Gas chromatographic retention indices of toxicologically relevant substances and their metabolites (Report of the DFG commission for clinical toxicological analysis, special issue of the TIAFT bulletin). VCH Publishers, WeinheimGoogle Scholar
  31. 31.
    McLafferty FW (2011) Wiley registry of mass spectral data 9th edition with NIST 2011 spectral data. Wiley, New YorkGoogle Scholar
  32. 32.
    Sharma V, McNeill JH (2009) Br J Pharmacol 157:907–921CrossRefGoogle Scholar
  33. 33.
    Maurer HH, Pfleger K, Weber AA (2013) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley, WeinheimGoogle Scholar
  34. 34.
    Maurer HH, Pfleger K, Weber AA (2014) Mass spectral library of drugs, poisons, pesticides, pollutants and their metabolites. Wiley, WeinheimGoogle Scholar
  35. 35.
    Wissenbach DK, Meyer MR, Remane D, Philipp AA, Weber AA, Maurer HH (2011) Anal Bioanal Chem 400:3481–3489CrossRefGoogle Scholar
  36. 36.
    Desta Z, Moaddel R, Ogburn ET, Xu C, Ramamoorthy A, Venkata SL, Sanghvi M, Goldberg ME, Torjman MC, Wainer IW (2012) Xenobiotica 42:1076–1087CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Markus R. Meyer
    • 1
  • Martina Bach
    • 1
  • Jessica Welter
    • 1
  • Michael Bovens
    • 2
  • Alain Turcant
    • 3
  • Hans H. Maurer
    • 1
  1. 1.Department of Experimental and Clinical Toxicology, Institute of Experimental and Clinical Pharmacology and ToxicologySaarland UniversityHomburg/SaarGermany
  2. 2.Forensic Science InstituteZürichSwitzerland
  3. 3.Laboratoire de Pharmacologie-ToxicologieCHUAngersFrance

Personalised recommendations